Shigemura, Tomonari
Perrot, Nahuel
Huang, Zimo
Bhatt, Rupal S.
Sheshdeh, Aseman Bagheri
Ahmar, Nourhan El
Ghandour, Fatme
Signoretti, Sabina
McDermott, David F.
Freeman, Gordon J.
Mahoney, Kathleen M.
Funding for this research was provided by:
National Institutes of Health (P50 CA101942, P50 CA101942, P50 CA101942, P50 CA101942, P50 CA101942, P50 CA101942, P50 CA101942, P50 CA101942, P50 CA101942, P50 CA101942, P50 CA101942)
Advanced Discovery Award from the Kidney Cancer Association ((2019–1517), (2019–1517), (2019–1517), (2019–1517), (2019–1517), (2019–1517))
U.S. Department of Defense, KCRP Concept Award (KC170139, KC170139, KC170139, KC170139, KC170139, KC170139, KC170139)
Article History
Received: 7 July 2023
Accepted: 9 October 2023
First Online: 27 October 2023
Declarations
:
: RCC samples were obtained from Beth Israel Deaconess Medical Center (BIDMC) from patients providing written consent under Renal cancer tissue collection protocol 01–130 approved by the Institutional Review Board (IRB) of the DanaFarber/Harvard Cancer Center (DF/HCC). Informed consent was obtained from all the participants and/or legal guardians for the study. PBMCs from anonymous donors were reviewed and approved in DF/HCC IRB-exempted protocol 93–011. All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Beth Israel Deaconess Medical Center (IACUC protocol number: 085–2020) and reported in accordance with ARRIVE guidelines.
: Not applicable.
: GJF has a patent application on targeting HHLA2 and KIR3DL3 for cancer immunotherapy, licensed to Nextpoint. GJF has patents/pending royalties on the PD-L1/PD-1 pathway from Bristol-Myers-Squibb, Roche, Eli Lilly, and Novartis. GJF has served on advisory boards for iTeos, NextPoint, IgM, GV20, IOME, Bioentre, Santa Ana Bio, Simcere of America, and Geode. GJF has equity in Nextpoint, Triursus, Xios, iTeos, IgM, Trillium, Invaria, GV20, Bioentre, and Geode. KM has research funding from Nextpoint Therapeutics. RBS is now an employee of Bristol-Myers Squibb. DFM has served on advisory boards for BMS, Pfizer, Merck, Eisai, Xilio, Aveo, Genentech, Cullinan, and Exelixis. SS reports receiving commercial research grants from Bristol-Myers Squibb, AstraZeneca, Exelixis and Novartis; is a consultant/advisory board member for Merck, AstraZeneca, Bristol Myers Squibb, CRISPR Therapeutics AG, AACR, and NCI; receives royalties from Biogenex; and mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/Foreign Components. TS, NP, ZH, ABS, NEA, FG declare no competing interests.